clinical trial · NCT06667908
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Johnson & Johnson Enterprise Innovation Inc.·phase2·recruiting·n = 130
Carcinoma, Non-Small-Cell LungJNJ-90301900DurvalumabConcurrent Chemo/Radiation Therapy (cCRT)Concurrent Chemo/Radiation Therapy (cCRT): CarboplatinConcurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
brief summary
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
started
Dec 6, 2024
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Apr 14, 2026
official title
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol